Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntingtons Disease and Establishes Clinical Advisory Board
HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled…
NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer
NEW YORK, Feb. 3, 2026 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Begin Trading on NYSE in Record Transfer
NEW YORK, Feb. 2, 2026 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market Update + Cast of HBO’s ‘Industry’ Rang Thursday’s Closing Bell
NEW YORK, Jan. 30, 2026 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market Update + York Space Systems to Debut on NYSE After IPO
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market Update + First Lady Melania Trump to Ring NYSE Bell for Doc ‘Melania’
NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market update + Block Exceeds $200 Billion in Credit Provided to Its Users
NEW YORK, Jan. 27, 2026 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market update + ICE Data Projects Coldest Stretch for U.S. in Decades
NEW YORK, Jan. 26, 2026 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market Update + Crypto Infrastructure Company BitGo Rises 2.7% in NYSE Debut
NEW YORK, Jan. 23, 2026 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market Update + Crypto Firm BitGo Prices NYSE IPO Above Range at $18 a Share
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- The New York Stock Exchange…
